Amgen’s Cholesterol Drug Cuts First‑Time Cardiac Event Risk by 25%

Amgen Inc.’s injectable cholesterol treatment Repatha reduced the risk of a first major cardiovascular event—such as a heart attack or stroke—by 25% in patients who had never had one, according to a study of over 12,000 people presented at the American Heart Association meeting in New Orleans. Notably, the treatment cut the risk of a first heart attack by 36%. It also lowered the relative risk of cardiovascular death by 21%, although that result did not reach statistical significance. Repatha belongs to the PCSK9‑inhibitor class that targets the PCSK9 protein to help lower LDL (“bad”) cholesterol—a pathway especially useful for patients who don’t respond to standard statin therapy. The results are significant because they mark the first time a PCSK9 inhibitor has been shown to reduce the risk of a first cardiovascular event (primary prevention) rather than only for patients who’ve already suffered heart disease. Previously, the Food and Drug Administration (FDA) broadened Repatha’s approval in August to include adults with uncontrolled LDL cholesterol at high cardiovascular risk—even if they hadn’t yet had a heart attack or stroke. For the first nine months of 2025, Repatha’s sales climbed 33% year‑on‑year to US $2.15 billion, reflecting its growing market share in the lipid‑lowering space. #Amgen #Repatha #CardiovascularPrevention #CholesterolTherapy #SlimScan #GrowthStocks #CANSLIM